

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 January 2005 (13.01.2005)

PCT

(10) International Publication Number
WO 2005/003776 A2

(51) International Patent Classification⁷: **G01N 33/574**

(21) International Application Number:
PCT/EP2004/007195

(22) International Filing Date: 30 June 2004 (30.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
200301518 30 June 2003 (30.06.2003) ES

(71) Applicant (for all designated States except US): **PROGENIKA BIOPHARMA, S.A.** [ES/ES]; Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta, E-48160 Derio (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GÓMEZ ROMÁN, José, Javier** [ES/ES]; Progenika Biopharma, S.A., Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta, E-48160 Derio (ES). **SÁENZ, JIMÉNEZ, María, Pilar** [ES/ES]; Progenika Biopharma, S.A., Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta, E-48160 Derio (ES). **OCHOA GARAY, Jorge** [ES/ES]; Progenika Biopharma, S.A., Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta, E-48160 Derio (ES). **DEL AMO IRIBARREN, Jokín** [ES/ES]; Progenika Biopharma, S.A., Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta, E-48160 Derio (ES). **SANZ IBAYONDO, Cristina** [ES/ES]; Progenika Biopharma, S.A., Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta, E-48160 Derio (ES). **JUNQUERA SÁNCHEZ-VALLEJO, Corina** [ES/ES]; Progenika Biopharma, S.A., Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta, E-48160 Derio (ES). **SIMÓN BUELA, Laureano** [ES/ES]; Progenika Biopharma, S.A., Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta, E-48160 Derio (ES). **MARTÍNEZ MARTÍNEZ, Antonio** [ES/ES]; Progenika Biopharma, S.A., Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta,

E-48160 Derio (ES). **ARGÜELLES SÁNCHEZ, María Eladla** [ES/ES]; Progenika Biopharma, S.A., Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta, E-48160 Derio (ES). **VAL BERNAL, José Fernando** [ES/ES]; Progenika Biopharma, S.A., Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta, E-48160 Derio (ES). **CUEVAS GONZÁLEZ, Jorge** [ES/ES]; Progenika Biopharma, S.A., Parque Tecnológico de Zamudio, Ibaizabal Bidea-Edificio 801-A 2a Planta, E-48160 Derio (ES).

(74) Agent: **PORTELA, Sergio**; ABG Patentes, S.L., Orense 16 8°A, E-28020 Madrid (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i)) for all designations

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: *IN VITRO* METHODS FOR DETECTING RENAL CANCER

(57) Abstract: The present invention refers to an *in vitro* method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression.

WO 2005/003776 A2